Wednesday, 01 Apr 2020

You are here

Best of 2019 - New EULAR/ACR Classification Criteria for SLE

The European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR) have jointly developed new classification criteria for systemic lupus erythematosus (SLE); prompted by the need for criteria that were both highly sensitive and specific.  The net result is improved sensitivity and specificity, but the use of positive ANA requirement along with a longer list of weighted criteria ensures its utility in SLE research (including early or latent SLE), but not clinical practice.

This international initiative from many lupus research centers had four phases.

  1. Evaluation of antinuclear antibody (ANA) as an entry criterion
  2. Criteria reduction by Delphi and nominal group technique exercises
  3. Criteria definition and weighting
  4. Refinement of weighting and threshold scores in a new cohort of 1,001 subjects and validation compared with previous criteria in a new validation cohort of 1,270 subjects.

The process included 23 expert centers, with each contributing up to 100 SLE patients and non-SLE patients. Diagnoses were verified by 3 independent reviewers for 1,193 SLE and 1,059 non-SLE patients. 500 randomly selected SLE and non-SLE patients formed the derivation cohort and the remainder the validation cohort. 

Past criteria were either too sensitive (1982, revised 1997) or too sensitive with a loss of specificity (SLICC 2012). Thus the new criteria set out to improve both the sensitivity and specificity.

 

ACR 1997

SLICC 2012

New criteria 2019

Derivation

  Sensitivity %

85

97

98

  Specificity %

95

90

96

Validation

  Sensitivity %

83

97

96

  Specificity %

93

84

93

The new 2019 EULAR/ACR classification criteria for SLE requires a positive ANA as obligatory entry criterion. Other criteria were chosen from 7 clinical (constitutional, hematologic, neuropsychiatric, mucocutaneous, serosal, musculoskeletal, renal) and 3 immunologic (antiphospholipid antibodies, complement proteins, SLE-specific antibodies) categories, and weighted from 2 to 10.

Patients with ≥10 points are classified as having SLE

In the validation cohort, the new criteria had a sensitivity of 96.1% and specificity of 93.4%, compared with 82.8% sensitivity and 93.4% specificity of the ACR 1997 and 96.7% sensitivity and 83.7% specificity of the Systemic Lupus International Collaborating Clinics 2012 criteria.

The following algorithm outlines the weighted point system used to classify a patient as SLE:

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

In Lupus, Keep BP Below 130/80

Blood pressure should be maintained at a level below 130/80 mm Hg in all patients with lupus to lessen their likelihood of atherosclerotic vascular events, Canadian researchers asserted.

In Vasculitis, Beware of Infection

Risks of infection were strikingly high among patients with antineutrophil cytoplasmic antibody-associated (ANCA) vasculitis, which may relate to both the disease and its treatment, Scottish researchers found.

Malignancies with Giant Cell Arteritis

The Journal of Rheumatology reports the findings of a Swedish population-based cohort study of biopsy-proven giant cell arteritis (GCA) patients showing that the overall risk for cancer was not increased; yet there appears to be an increased risk for leukemia and a decreased risk for breast and upper gastrointestinal tract cancers.   

Hospitalized GPA - Higher morbidity, Mortality and Cost

Rheumatology reports on a study of patients with granulomatosis with polyangiitis (GPA) showing worse outcomes and higher costs when hospitalized with GPA.

GPA patients were identified from the Nationwide Inpatient Sample (NIS) and were compared to those without GPA with regard to demographics, procedures, length of stay, mortality, morbidity and total hospitalization charges (between 2005–2014).

Don't Blame the Weather in Sjogren's

Seasonal variations in symptoms -- commonly reported by patients with rheumatic diseases -- were not observed in a large cohort of patients with primary Sjogren's syndrome, French investigators found.